21-11-2012

Avita Medical Ltd. has initiated a multicenter randomized control study on the use of ReCell® Spray-On Skin® in the treatment of venous leg ulcers. Up to five European centres from countries including the United Kingdom, Germany, France and Denmark will participate in the study.Lower limb ...

more

24-04-2012

Adocia announced positive results from its Phase II clinical trial evaluating the safety and efficacy of BioChaperone(R) combined with PDGF-BB for the treatment of diabetic foot ulcer. This product has been compared with Regranex(R), a commercially available hydrogel of PDGF-BB (HealthPoint, ...

more

09-02-2010

Sorbus Pharmaceuticals GmbH announced its incorporation in Vienna, Austria. Sorbus discovers and develops novel treatments for complicated wounds, cancer and other life-threatening diseases. Its lead drug, SertaSil, has demonstrated exceptional effects in patients with acute and chronic ...

more

24-11-2009

Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies failed to show superiority of SBG vs. placebo in terms of ulcer healing, and the company will thus not proceed with ...

more

07-07-2009

Kuros Biosurgery AG announced that it has treated the first patient in a Phase IIb clinical trial investigating KUR­211 (Viz.I-020201) in the treatment of diabetic foot ulcers. KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant ...

more

15-05-2009

The independent statistician responsible for the interim analysis of the second of the two phase III studies with SBG for diabetic foot ulcers recommends that Biotec Pharmacon proceeds as planned with the study. As no adjustments are being made to sample size, patient enrolment is already ...

more

Pipeline to include novel oncology therapy, talactoferrin, which recently entered Phase 3 clinical testing

20-02-2009

GPC Biotech AG and Agennix, Incorporated announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses. In the transaction, GPC Biotech is to be merged onto a new German company, which will ...

more

Near-Term Commercialization Opportunities from Innovive’s Oncology Portfolio Complement CytRx Molecular Chaperone Pipeline and Technology Platform

25-09-2008

CytRx Corporation announced the completion of its acquisition of Innovive Pharmaceuticals, Inc. CytRx purchased Innovive for total consideration of approximately 2.6 million shares of CytRx common stock, approximately $18.3 million of future performance-based milestone earn-outs, and the ...

more

28-02-2006

Biotec Pharmacon has entered into an agreement with Nottingham City Hospital NHS Trust to perform a clinical phase II study entitled "A randomised, double-blind, placebo-controlled study to determine the efficacy of soluble beta-1,3/1,6-glucan in chronic foot ulcers in diabetes." A total of ...

more

15-12-2004

Despite the ongoing risks and costs of drug development, as well as a continuing of a general 'low ebb' in the industry, new players are using partnering tactics to build a presence in the global pharmaceutical market, most notably South Korea. Like many other emerging pharmaceutical sectors ...

more